Study on TIL for the Treatment of r/r Gynecologic Tumors

Gynecologic Cancer Clinical Trial

Official title:

A Clinical Safety and Efficacy Study on TIL for the Treatment of r/r Gynecologic Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04766320
• Other study ID #: shiyuanfuke000
• Status: Recruiting
• Phase: Phase 1
• Start date: January 4, 2021
• Est. completion date: January 31, 2025

Study information

• Verified date: March 2024
• Source: Shanghai 10th People's Hospital
• Contact: Jing Guo, PHd
• Phone: +86 21 66307151
• Email: jguo12[@]foxmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gynecologic tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: January 31, 2025
• Est. primary completion date: December 4, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age: 18 years to 75 years;

2. Histologically diagnosed as primary/relapsed/metastasized malignant tumors;

3. Expected life-span more than 3 months;

4. Karnofsky=60% or ECOG score 0-2;

5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.

6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;

7. At least 1 evaluable tumor lesion;

8. Absolute count of white blood cells=2.5×10^9/L, absolute count of neutropils=1.5×10^9/L, platelet count=100×10^9, hemoglobin=90 g/L;

9. Serum creatinine clearance 50mL/min or higher; creatinine=1.5×ULN; ALT/AST less than three times that of normal group, ALT/AST of test subjects with liver metastasis less than five times that of normal group; bilirubin=1.5×ULN;

10. Activated partial thromboplastin time (APTT) less than or equal to 1.5xULN; international normalized ratio (INR) less than or equal to 1.5xULN;

11. Enough venous accessibility, no absolute or relative contraindications to operation or biopsy;

12. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion;

13. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;

14. Be able to understand and sign the informed consent document;

15. Be able to stick to follow-up visit plan and other requirements in the agreement.

Exclusion Criteria:

1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones);

2. Autoimmune diseases requiring immunomodulatory treatment;

3. Serum creatinine >1.5×ULN; serum glutamic-oxalacetic transaminase (SGOT) greater than 5×ULN; bilirubin >1.5×ULN;

4. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;

5. Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.

6. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;

7. Severe physical or mental diseases;

8. Blood culture positive or imaging proof;

9. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;

10. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;

11. Having received immunotherapy and developed irAE level greater than Level 3;

12. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);

13. Females in pregnancy or lactation;

14. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.

Related Conditions & MeSH terms

• Genital Neoplasms, Female
• Gynecologic Cancer

Intervention

Biological:
• Tumor Infiltrating Lymphocytes (TIL)
Adoptive transfer of 1x10^9-3x10^11 autologous TILs to patients i.v. in 30-120 minutes.

Locations

Country	Name	City	State
China	Shanghai Tenth People's Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai 10th People's Hospital	Shanghai Juncell Therapeutics

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Serious Adverse Events (SAEs)	Safety assessments. Incidence of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs). The severity of all adverse events was graded based on Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.	Up to 12 months
Secondary	Objective Response Rate (ORR)	To evaluate the efficacy of TIL infusion in patients as determined by objective response rate (ORR), which contains complete response (CR) and partial response (PR), using the RECIST v1.1, as assessed by the Investigator. ( CT Scan at 4-6 weeks after TIL infusion, and than every 4-6 weeks for 1 year, and then every six months after that for up to 3 years)	Up to 36 months
Secondary	Disease Control Rate (DCR)	Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST 1.1	Up to 36 months
Secondary	Duration of Response (DOR)	The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1	Up to 36 months
Secondary	Progression-Free Survival (PFS)	The time length between TIL infusion and confirmed subsequent disease progression according to RECIST 1.1	Up to 36 months
Secondary	Overall Survival (OS)	The length of time from the date of the start of TIL treatment that the patients are still alive	Up to 36 months
Secondary	Complete Response(CR)	Patients with complete response per RECIST 1.1 to TIL treatment	Up to 36 months
Secondary	Partial Response (PR)	Percentage of patients with partial response per RECIST 1.1 to TIL treatment	Up to 36 months
Secondary	Stable Disease (SD)	Patients with stable disease per RECIST 1.1 to TIL treatment	Up to 36 months
Secondary	Progressive Disease (PD)	Patients with progressive disease per RECIST 1.1 to TIL treatment	Up to 36 months